Surmodics (NASDAQ:SRDX) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Surmodics (NASDAQ:SRDX) has received a "Sell (D-)" rating from Weiss Ratings, indicating a negative outlook for the stock.
• The company recently reported earnings of $0.06 per share, surpassing expectations, but has a negative net margin of 14.59%.
• Institutional investors dominate Surmodics' ownership, holding 96.63% of the company's stock, reflecting strong investment interest despite rating concerns.

Surmodics (NASDAQ:SRDX - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a research note issued to investors on Wednesday,Weiss Ratings reports.

Several other equities research analysts have also recently issued reports on SRDX. Barrington Research reaffirmed a "market perform" rating on shares of Surmodics in a research note on Monday, August 11th. Zacks Research raised shares of Surmodics to a "hold" rating in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $43.00.

Surmodics Trading Down 0.4%

Shares of SRDX opened at $28.71 on Wednesday. Surmodics has a 52-week low of $26.00 and a 52-week high of $40.38. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27. The firm's fifty day moving average is $33.50 and its two-hundred day moving average is $30.94. The stock has a market cap of $410.55 million, a PE ratio of -23.34 and a beta of 1.31.

Surmodics (NASDAQ:SRDX - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.27. Surmodics had a negative net margin of 14.59% and a negative return on equity of 2.99%. The company had revenue of $29.57 million for the quarter, compared to analysts' expectations of $28.04 million. Surmodics has set its FY 2025 guidance at -0.350--0.200 EPS. Research analysts forecast that Surmodics will post 0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. lifted its position in Surmodics by 705.9% in the second quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company's stock valued at $37,000 after buying an additional 1,080 shares during the last quarter. BNP Paribas Financial Markets lifted its position in Surmodics by 67.6% in the second quarter. BNP Paribas Financial Markets now owns 1,435 shares of the company's stock valued at $43,000 after buying an additional 579 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Surmodics by 289.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,730 shares of the company's stock valued at $51,000 after buying an additional 1,286 shares during the last quarter. Strs Ohio acquired a new position in Surmodics in the first quarter valued at about $122,000. Finally, AlphaQuest LLC acquired a new position in Surmodics in the first quarter valued at about $232,000. Institutional investors and hedge funds own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.